964
Views
6
CrossRef citations to date
0
Altmetric
Review

BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

ORCID Icon, , , , , , , , , , , , ORCID Icon & show all
Pages 847-857 | Received 28 Jul 2018, Accepted 01 Oct 2018, Published online: 24 Oct 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Simone Salemme, Antonio Ancidoni, Nicoletta Locuratolo, Paola Piscopo, Eleonora Lacorte, Marco Canevelli & Nicola Vanacore. (2023) Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues. Expert Review of Neurotherapeutics 0:0, pages 1-17.
Read now
Francesco Panza, Maddalena La Montagna, Luisa Lampignano, Roberta Zupo, Ilaria Bortone, Fabio Castellana, Rodolfo Sardone, Luisa Borraccino, Vittorio Dibello, Emanuela Resta, Mario Altamura, Antonio Daniele & Madia Lozupone. (2021) Vitamin D in the development and progression of alzheimer’s disease: implications for clinical management. Expert Review of Neurotherapeutics 21:3, pages 287-301.
Read now
Natalia Szałaj, Justyna Godyń, Jakub Jończyk, Anna Pasieka, Dawid Panek, Tomasz Wichur, Krzysztof Więckowski, Paula Zaręba, Marek Bajda, Anja Pislar, Barbara Malawska, Raimon Sabate & Anna Więckowska. (2020) Multidirectional in vitro and in cellulo studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 1944-1952.
Read now
Sheila A. Doggrell. (2019) Lessons that can be learnt from the failure of verubecestat in Alzheimer’s disease. Expert Opinion on Pharmacotherapy 20:17, pages 2095-2099.
Read now
Juan F. González, Andrés R. Alcántara, Antonio L. Doadrio & Jose María Sánchez-Montero. (2019) Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery 14:9, pages 879-891.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.